

ANTARES PHARMA INC  
Form 8-K  
May 15, 2007  
UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 11, 2007

**Antares Pharma, Inc.**

(Exact Name of Registrant Specified in Charter)

<b>Delaware</b>	<b>1-32302</b>	<b>41-1350192</b>
(State or Other	(Commission File	(I.R.S. Employer
Jurisdiction of	Number)	Identification No.)
Incorporation)		

**250 Phillips Blvd., Suite 290, Ewing, NJ**  
(Address of Principal Executive Offices)

**08618**  
(Zip Code)

Registrant's telephone number, including area code **609-359-3020**

**Not Applicable**  
(Former Name or Former Address, if Changed Since Last Report)

Edgar Filing: ANTARES PHARMA INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.03 Amendment to Articles of Incorporation or Bylaws; Change in Fiscal Year**

On August 8, 2006, the Securities and Exchange Commission approved new AMEX listing standards setting forth Direct Registration System ( DRS ) eligibility requirements. DRS enables investors to maintain securities electronically on the books of a transfer agent or issuer, and allows for the electronic transfer of securities. To meet DRS requirements, on May 11, 2007, the Company s Board of Directors amended and restated its bylaws to permit the issuance and transfer of uncertificated shares.

A copy of the Amended and Restated Bylaws is attached as Exhibit 3.1 and incorporated into this Item 5.03 by reference.

**Item 9.01 Financial Statements and Exhibits.**

(c) Exhibits.

3.1 Amended and Restated Bylaws of Antares Pharma, Inc.

1-PH/2661277.1

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANTARES PHARMA, INC.**

Date: May 15, 2007

By: ROBERT F. APPLE  
**Robert F. Apple**

**Chief Financial Officer**

---

**EXHIBIT INDEX**

**Exhibit Number**

**Document**

3.1

Amended and Restated Bylaws of Antares Pharma, Inc.